Drug intelligence / Profile preview

nedizantrep

Development stage: Phase 2
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral

Overview

Nedizantrep (GDC-6599) is an orally active, small molecule inhibitor of the transient receptor potential cation channel subfamily A member 1 (TRPA1). It is being developed primarily for the treatment of chronic cough and asthma. Nedizantrep acts by selectively inhibiting TRPA1, a sensory ion channel implicated in neurogenic inflammation and cough reflex pathways. The drug has demonstrated potent inhibition of TRPA1 across multiple species and has advanced to Phase II clinical trials for refractory or unexplained chronic cough, with additional studies in asthma. Nedizantrep was developed by Genentech, a subsidiary of F. Hoffmann-La Roche[1][2][3][4][5][6].

Other names: nedizantrep

Targets

TRPA1 (Transient receptor potential cation channel subfamily A member 1)

Beyond the preview

Go deeper on nedizantrep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nedizantrep.

Explore the full profile